# Spain Brucellosis Market > Spain Brucellosis Market Research Report: Size, Share, Trend Analysis By species (Brucella suis, B. abortus, B. melitensis) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.42% - **2024:** $ 16.44 Million - **2025:** $ 17.5 Million - **2035:** $ 32.59 Million - **Key Players:** Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR) **Report ID:** MRFR/LS/51837-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/spain-brucellosis-market-53598 --- ## Market Summary ## **Spain Brucellosis Market Overview** As per MRFR analysis, the Spain Brucellosis Market Size was estimated at 4.27 (USD Million) in 2023.The Spain Brucellosis Market is expected to grow from 4.65(USD Million) in 2024 to 12.5 (USD Million) by 2035. The Spain Brucellosis Market CAGR (growth rate) is expected to be around 9.406% during the forecast period (2025 - 2035). **Key Spain Brucellosis Market Trends Highlighted** Growing awareness of and attempts to improve animal health and food safety are driving significant trends in the brucellosis market in Spain. Better diagnosis and immunization techniques have resulted from the Spanish government's stringent laws and surveillance efforts to combat brucellosis, especially in animals. The need for vaccinations and testing services to maintain herd health is growing as farmers and livestock producers become more aware of disease control. The development of vaccines and improvements in diagnostic technology are the main areas of opportunity in the Spanish brucellosis market. Using rapid testing kits helps speed up results and stop the disease from spreading, which is important for public health and the farm industry. Furthermore, there is an opportunity to simplify disease monitoring and management through the integration of digital health solutions and veterinary services, which will assist farmers in more efficiently maintaining healthier cattle. Recent trends show that the public and private sectors are increasingly working together to improve Brucellosis research and development projects. This involves collaborations between educational institutions and farming associations to provide creative answers to the particular problems facing the Spanish cattle sector. A comprehensive approach to disease control is also being promoted by the growing number of educational initiatives that target producers and consumers regarding the significance of vaccination and biosecurity measures. These coordinated actions demonstrate a dedication to maintaining animal health and market stability in Spain and represent a proactive response to the Brucellosis danger. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Spain Brucellosis Market Drivers** **Increasing Livestock Farming Activities in Spain** In Spain, livestock farming is an integral part of the economy, being one of the largest agricultural sectors contributing significantly to regional GDP. According to the Ministry of Agriculture, Fisheries and Food, Spain has over 28 million cattle, which are susceptible to Brucellosis. This significant population creates a continuous demand for effective veterinary healthcare solutions, particularly in managing and controlling Brucellosis outbreaks. Given the current increase in livestock populations and farming activities, the Spain [Brucellosis Market](../../../reports/brucellosis-market-5159) is expected to see robust growth as farmers invest in vaccines and diagnostic tests. Moreover, the European Union is implementing stricter regulations to ensure livestock health and control zoonotic diseases like Brucellosis, further enhancing market prospects. **Government Initiatives and Funding for Disease Control** The Spanish government has been proactive in addressing public health issues related to livestock diseases, including Brucellosis. The Ministry of Agriculture has allocated significant funding towards the control and eradication of Brucellosis through vaccination programs and public awareness campaigns. Such initiatives not only aim to protect animal health but also ensure food safety for consumers. The National Program for the Prevention and Control of Brucellosis has been instrumental in raising awareness among farmers and enhancing the use of vaccines. This funding leads directly to an expected growth in the Spain Brucellosis Market as the government supports improved diagnostic capabilities and veterinary services. **Rising Awareness of Zoonotic Diseases** In recent years, there has been a marked increase in the awareness of zoonotic diseases among the Spanish population, particularly following recent health crises. Organizations such as the World Health Organization and local health bodies have ramped up educational initiatives regarding zoonotic diseases, including Brucellosis. As the public becomes increasingly informed about the implications of these diseases for human health, there is a strong push for improved vaccination and prevention strategies within the livestock sector. This trend drives demand for veterinary vaccines and testing solutions in the Spain Brucellosis Market, as both farmers and consumers seek to mitigate health risks associated with livestock. **Spain Brucellosis Market Segment Insights** **Brucellosis Market species Insights** The Spain Brucellosis Market is primarily segmented into various species, with Brucella suis, B. abortus, and B. melitensis being the key representatives. Brucella suis mainly affects swine and poses a considerable risk to livestock health within Spain, influencing both the agricultural economy and food safety protocols. The significance of this species extends beyond livestock, as it can be transmitted to humans, highlighting the need for effective control measures. B. abortus primarily impacts cattle and is associated with reproductive issues, making it a vital concern for the beef and dairy industry in Spain. Given Spain's robust livestock sector, containing this pathogen is crucial for maintaining herd productivity and ensuring consumer safety. B. melitensis is known for its prevalence in goats and sheep, presenting challenges in terms of zoonotic transmission to humans, thereby emphasizing the importance of public health initiatives aimed at controlling this pathogen in livestock. The geographic distribution of these species across Spain also varies, contributing to the differential management approaches needed for effective control and prevention of brucellosis outbreaks. Overall, the species segmentation within the Spain Brucellosis Market showcases the significant risk factors associated with livestock transmission, impacting not only agriculture but also broader public health policies. Understanding these species and their implications is crucial for stakeholders in agriculture and health sectors alike, as they navigate the complexities of brucellosis management and strive to mitigate its impact on both economic and health fronts. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Spain Brucellosis Market Key Players and Competitive Insights** The Spain Brucellosis Market is characterized by a competitive landscape influenced by various factors, including the prevalence of this zoonotic disease in livestock, regulatory frameworks governing animal health, and the increasing emphasis on food safety and public health. The market features a blend of local and international players that strive to provide effective solutions in the form of vaccines, diagnostics, and treatment options. In recent years, the market has witnessed a push towards innovation, with companies seeking to enhance their offerings through research and development initiatives. Moreover, collaborations and strategic partnerships among industry stakeholders are becoming crucial in driving market growth and expansion. The competitive dynamics are further shaped by the demand for effective disease management in agriculture and livestock sectors, highlighting the importance of tailoring products and services to meet specific regional needs. Elanco stands out in the Spain Brucellosis Market due to its robust portfolio of veterinary pharmaceuticals and vaccines. The company's strengths lie in its commitment to research and development, allowing it to offer reliable solutions that address the challenges posed by brucellosis. Elanco has established a significant market presence in Spain, recognized for its scientific expertise and customer-centric approach. Its products are designed to ensure animal health and well-being, thereby enhancing productivity in livestock sectors. Additionally, Elanco’s strategic relationships with local veterinarians and livestock producers enable it to effectively meet customer needs, making it a trusted partner in managing brucellosis and other related diseases. Fornetti has also made a noteworthy impact on the Spain Brucellosis Market, primarily through its dedication to providing high-quality animal health solutions. The company emphasizes innovative product development and has successfully introduced several key products focused on the prevention and management of brucellosis. Fornetti's strengths include a solid distribution network and effective marketing strategies that resonate well with local farmers and veterinarians. The company has identified key opportunities for collaboration and partnerships, allowing it to expand its market footprint in Spain. Furthermore, Fornetti is known for its proactive approach towards mergers and acquisitions, which bolsters its capacity for rapid growth and adaptability in the competitive landscape. This ongoing commitment to innovation and collaboration positions Fornetti favorably within the Spanish market for brucellosis solutions. **Key Companies in the Spain Brucellosis Market Include** - Elanco - Fornetti - Intervet - Hipra - Neogen - Biomapas - Vetoquinol - IDT Biologika - Merck Animal Health - Boehringer Ingelheim - CEVA Santé Animale - Virbac - Oxford Immunotec - Pfeiffer - Zoetis **Spain Brucellosis****Market****Developments** Recent developments in the Spain Brucellosis Market highlight significant advancements in control measures against the disease affecting livestock. The Spanish government has been actively promoting vaccination programs, which have seen increased involvement from companies like Elanco and Intervet, focusing on innovative vaccine solutions tailored to local breeds. In September 2023, it was reported that Hipra launched a new diagnostic tool aimed at early detection of brucellosis in cattle, improving overall herd management. Furthermore, Merck Animal Health has reported a continuous investment in Research and Development to enhance their product offerings in this market, while Vetoquinol has collaborated with local veterinary services to strengthen the health infrastructure against brucellosis outbreaks. The market has also seen M&A activity, with Zoetis acquiring a local biotech firm specializing in veterinary vaccines in August 2023, signaling a trend towards consolidation among major players such as Boehringer Ingelheim and CEVA Santé Animale. Overall, these developments demonstrate the increasing focus on eradicating brucellosis and improving animal health metrics across Spain, reflecting the livestock sector's critical importance to the nation’s economy and food security. **Spain Brucellosis Market Segmentation Insights** **Brucellosis Market species Outlook** - Brucella suis - B. abortus - B. melitensis ## Market Drivers ### Government Initiatives and Funding Government initiatives aimed at controlling zoonotic diseases, including brucellosis, play a pivotal role in shaping the brucellosis market. The Spanish Ministry of Health has introduced various programs to enhance surveillance and control measures, which include funding for vaccination campaigns and public awareness initiatives. In 2025, the government has earmarked an additional €1.5 million specifically for brucellosis research, which is expected to bolster the market. These initiatives not only aim to reduce the incidence of the disease but also encourage collaboration between public health agencies and private sector stakeholders. As a result, the brucellosis market is likely to experience growth driven by increased investment in research and development, ultimately leading to improved health outcomes. ### Advancements in Veterinary Practices Advancements in veterinary practices are significantly influencing the brucellosis market in Spain. The integration of modern diagnostic tools and vaccination protocols in livestock management has shown to reduce the prevalence of brucellosis among cattle and sheep. Recent studies suggest that effective vaccination can decrease infection rates by up to 30%, thereby enhancing herd health and productivity. As veterinarians adopt these advanced practices, the demand for related products and services in the brucellosis market is expected to rise. Furthermore, the collaboration between veterinary professionals and agricultural stakeholders is likely to foster innovation, leading to the development of more effective vaccines and diagnostic tests, which could further stimulate market growth. ### Rising Incidence of Brucellosis Cases The increasing incidence of brucellosis cases in Spain is a critical driver for the brucellosis market. Reports indicate that the number of reported cases has risen by approximately 15% over the past five years, prompting heightened awareness and response from health authorities. This trend necessitates the development and distribution of effective vaccines and diagnostic tools, thereby stimulating market growth. The Spanish government has allocated €2 million for research and development in this area, indicating a commitment to combatting the disease. As the public health implications of brucellosis become more pronounced, the demand for innovative solutions in the brucellosis market is likely to escalate, creating opportunities for stakeholders to invest in preventive measures and treatments. ### Rising Demand for Diagnostic Solutions The rising demand for diagnostic solutions is a significant driver of the brucellosis market. With the increasing incidence of brucellosis, there is a pressing need for accurate and rapid diagnostic tests to facilitate timely treatment and control measures. The market for diagnostic tools is projected to grow by approximately 10% annually, driven by advancements in technology and the need for effective disease management. In Spain, the introduction of new diagnostic kits that provide results within hours has been particularly well-received. This trend indicates a shift towards more efficient disease management strategies, which is likely to further enhance the brucellosis market as stakeholders seek to invest in innovative diagnostic solutions. ### Increased Public Awareness and Education Increased public awareness and education regarding brucellosis are driving factors in the brucellosis market. Campaigns aimed at educating farmers and the general public about the transmission and prevention of brucellosis have gained momentum in recent years. These initiatives have reportedly led to a 20% increase in vaccination rates among livestock, which is crucial for controlling the disease. As awareness grows, the demand for educational resources and preventive measures is likely to expand, creating opportunities for companies within the brucellosis market. The emphasis on education not only helps in reducing the incidence of the disease but also encourages responsible practices among livestock owners, thereby contributing to overall market growth. ## Future Outlook The [Brucellosis Market](https://www.marketresearchfuture.com/reports/brucellosis-market-5159) in Spain is projected to grow at a 6.42% CAGR from 2025 to 2035, driven by increased awareness, advancements in diagnostics, and enhanced vaccination programs. **New opportunities:** - Development of mobile diagnostic units for remote testing. - Investment in advanced vaccine research for livestock. - Partnerships with agricultural cooperatives for awareness campaigns. By 2035, the market is expected to achieve robust growth, driven by strategic innovations and partnerships. ## Segment Insights ### By Species: Brucella melitensis (Largest) vs. Brucella suis (Fastest-Growing) The Spain brucellosis market showcases a diverse distribution of species, with Brucella melitensis commanding the largest market share due to its extensive prevalence in livestock and its significant impact on public health. Brucella suis follows closely, reflecting growing attention in specific animal husbandry practices. Other species like Brucella abortus and Brucella canis also contribute to the landscape but to a lesser extent, highlighting the varying levels of awareness and testing in different regions. As the market evolves, growth trends indicate a significant spike in the interest in Brucella suis, largely driven by emerging veterinary practices and increased funding for disease control programs. Education on zoonotic diseases, coupled with stricter regulations, pushes the demand for effective management strategies, propelling Brucella suis as the fastest-growing segment. The awareness of Brucella melitensis, while still dominant, necessitates continuous efforts to mitigate outbreaks and enhance detection protocols. Brucella melitensis (Dominant) vs. Brucella suis (Emerging) Brucella melitensis stands out as the dominant species in the Spain brucellosis market, primarily affecting sheep and goats, which are key to the agricultural sector. This species is characterized by its ability to cause severe health issues, fostering strong measures for control and prevention among local authorities. In contrast, Brucella suis, which predominantly affects swine, is emerging rapidly due to increased incidences reported in pig farming, leading to heightened awareness and strategic interventions. While Brucella melitensis maintains its stronghold, Brucella suis is positioned uniquely to capture further market share as veterinary practices advance and more farmers recognize the importance of biosecurity and disease management. ### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing) In the Spain brucellosis market, serological tests hold the largest share among the diagnostic methods due to their widespread usage and reliability for initial screening. These tests account for a significant portion of the total diagnostic evaluations due to their cost-effectiveness and quick turnaround times. Following closely are molecular techniques, which are emerging as the fastest-growing segment thanks to advancements in technology that enhance accuracy and speed in diagnosing brucellosis. The growth trends in this segment are primarily driven by the increasing awareness of brucellosis and the need for rapid diagnosis in both clinical and veterinary settings. The demand for accurate and reliable diagnostic tests is leading healthcare providers to adopt more sophisticated techniques, such as molecular methods, which are gaining traction for their high sensitivity and specificity. Furthermore, the integration of advanced imaging techniques is opening new avenues for diagnosis, indicating a promising trend for the future. Serological Tests (Dominant) vs. Molecular Techniques (Emerging) Serological tests remain the dominant diagnostic method in the Spain brucellosis market, primarily due to their established protocols and ease of implementation. These tests facilitate effective screening and monitoring, quickly identifying infected individuals through detectable antibodies. Conversely, molecular techniques are emerging with innovative approaches, such as polymerase chain reaction (PCR), which significantly enhance diagnostic precision and speed. These techniques have gained popularity among healthcare professionals as they offer the ability to detect brucella DNA, allowing for more targeted treatment options. The competitive landscape is evolving as more laboratories incorporate molecular diagnostics, signaling a shift towards more rapid and accurate identification methodologies. ### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing) In the Spain brucellosis market, the treatment segment displays a diverse market share distribution among antibiotics, vaccines, and other therapeutic options. Antibiotics hold the largest share, primarily due to their established use and efficacy in treating infections caused by the brucella bacteria. Vaccines, while having a smaller current share, are rapidly gaining traction as awareness of preventive measures increases, particularly in livestock management. Other treatments make up a smaller segment, focusing on supportive therapies and adjuncts to antibiotic treatment. The growth trends in the treatment segment are driven by increased focus on disease control and prevention strategies. The rising incidence of brucellosis infections necessitates not just treatment but also vaccination efforts in livestock to prevent outbreaks. The push towards more sustainable agricultural practices, combined with advancements in vaccine development, positions vaccines as the fastest-growing segment. This shift towards prevention complements traditional treatment options and is vital for an effective comprehensive strategy against brucellosis. Antibiotics (Dominant) vs. Vaccines (Emerging) Antibiotics dominate the treatment landscape in the Spain brucellosis market, recognized for their effectiveness in managing acute brucellosis infections. This dominance is supported by a range of antibiotic options that are both affordable and widely available, making them the first choice for many practitioners. On the other hand, vaccines are an emerging segment, seen as pivotal for long-term control of the disease. Their development has been spurred by a focus on prevention, with new formulations aimed at enhancing immunity among livestock. While antibiotics are essential for immediate treatment, the strategic incorporation of vaccines is expected to reshape the treatment paradigm, emphasizing preventive healthcare in livestock and addressing the broader implications of brucellosis control. ### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Academic Institutes (Fastest-Growing) In the Spain brucellosis market, the end-user segment exhibits a diverse distribution, with hospitals & diagnostic centers holding the largest share. These facilities form the backbone of diagnostics and treatment protocols for brucellosis, leveraging advanced technologies and comprehensive care systems. In contrast, academic institutes, while smaller in market share, are crucial for research and development, significantly contributing to the overall growth dynamics of the market. Growth trends for the end-user segment are being driven by an increasing focus on disease prevention and control, particularly within healthcare institutions. As the awareness of brucellosis and its impacts rises, hospitals and diagnostic centers are expanding their capabilities. Meanwhile, academic institutes are rapidly becoming important players by fostering innovation and collaborating with biotech firms, positioning them as the fastest-growing segment in this market. Hospitals & Diagnostic Centers (Dominant) vs. Academic Institutes (Emerging) Hospitals & diagnostic centers remain the dominant players in the end-user segment of the Spain brucellosis market, offering extensive testing and treatment options. Their infrastructure supports significant patient throughput and the application of cutting-edge diagnostic techniques. In contrast, academic institutes are emerging as vital contributors through research initiatives and the cultivation of new diagnostic tools. These institutions facilitate collaboration between academia and industry, enabling the swift translation of research findings into clinical practice. The synergy between established healthcare facilities and innovative academic programs fosters a holistic approach towards tackling brucellosis, ensuring comprehensive management strategies are in place. ## Competitive Benchmarking The brucellosis market exhibits a competitive landscape characterized by a blend of established players and emerging innovators. Key growth drivers include increasing awareness of animal health, stringent regulations regarding livestock diseases, and advancements in diagnostic technologies. Major companies such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are strategically positioned to leverage these trends. Zoetis (US) focuses on innovation in vaccine development, while Merck Animal Health (US) emphasizes partnerships to enhance its product portfolio. Boehringer Ingelheim (DE) is actively pursuing regional expansion, particularly in Southern Europe, to capture a larger market share. Collectively, these strategies foster a dynamic competitive environment, where innovation and regional presence are pivotal. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several players vying for dominance. This fragmentation allows for diverse offerings but also intensifies competition among key players. The collective influence of these companies shapes market dynamics, as they strive to differentiate themselves through unique value propositions and operational efficiencies. In October 2025, Zoetis (US) announced the launch of a new brucellosis vaccine aimed at improving livestock immunity. This strategic move is significant as it not only enhances Zoetis's product line but also addresses the growing demand for effective disease management solutions in the livestock sector. The introduction of this vaccine is likely to strengthen Zoetis's market position and reinforce its commitment to animal health innovation. In September 2025, Merck Animal Health (US) entered a strategic partnership with a leading veterinary diagnostic company to develop advanced testing solutions for brucellosis. This collaboration is crucial as it aligns with the increasing emphasis on rapid and accurate diagnostics in animal health. By integrating cutting-edge technology into its offerings, Merck aims to enhance its competitive edge and provide comprehensive solutions to veterinarians and livestock producers. In August 2025, Boehringer Ingelheim (DE) expanded its operations in Spain by establishing a new research facility dedicated to animal health. This investment underscores the company's commitment to innovation and its strategic focus on enhancing research capabilities in the region. The establishment of this facility is expected to facilitate the development of novel therapeutic solutions, thereby positioning Boehringer Ingelheim as a leader in the brucellosis market. As of November 2025, current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in veterinary practices. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technology, and supply chain reliability. This transition suggests that companies will need to invest in research and development to stay ahead in a rapidly changing market. ## Recent News & Developments Recent developments in the Spain Brucellosis Market highlight significant advancements in control measures against the disease affecting livestock. The Spanish government has been actively promoting vaccination programs, which have seen increased involvement from companies like Elanco and Intervet, focusing on innovative vaccine solutions tailored to local breeds. In September 2023, it was reported that Hipra launched a new diagnostic tool aimed at early detection of brucellosis in cattle, improving overall herd management. Furthermore, Merck Animal Health has reported a continuous investment in Research and Development to enhance their product offerings in this market, while Vetoquinol has collaborated with local veterinary services to strengthen the health infrastructure against brucellosis outbreaks. The market has also seen M&A activity, with Zoetis acquiring a local biotech firm specializing in veterinary vaccines in August 2023, signaling a trend towards consolidation among major players such as Boehringer Ingelheim and CEVA Santé Animale. Overall, these developments demonstrate the increasing focus on eradicating brucellosis and improving animal health metrics across Spain, reflecting the livestock sector's critical importance to the nation’s economy and food security. ## Report Scope | MARKET SIZE 2024 | 16.44(USD Million) | | --- | --- | | MARKET SIZE 2025 | 17.5(USD Million) | | MARKET SIZE 2035 | 32.59(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.42% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR) | | Segments Covered | Species, Diagnosis, Treatment, End-User | | Key Market Opportunities | Emerging diagnostic technologies enhance early detection and treatment options in the brucellosis market. | | Key Market Dynamics | Rising regulatory scrutiny and technological advancements drive innovation in brucellosis diagnostics and treatment solutions. | | Countries Covered | Spain | ## Frequently Asked Questions **Q: What was the overall market valuation of the Spain brucellosis market in 2024?** A: The overall market valuation was $16.44 Million in 2024. **Q: What is the projected market valuation for the Spain brucellosis market by 2035?** A: The projected valuation for 2035 is $32.59 Million. **Q: What is the expected CAGR for the Spain brucellosis market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 6.42%. **Q: Which companies are considered key players in the Spain brucellosis market?** A: Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, Virbac, Ceva Santé Animale, Heska Corporation, and Vetoquinol. **Q: What are the main segments of the Spain brucellosis market?** A: Main segments include species, diagnosis, treatment, and end-user. **Q: What was the valuation of the Brucella abortus segment in 2024?** A: The valuation of the Brucella abortus segment was $4.0 Million in 2024. **Q: How much is the Brucella melitensis segment projected to be valued by 2035?** A: The Brucella melitensis segment is projected to be valued at $10.0 Million by 2035. **Q: What is the projected valuation for antibiotics in the treatment segment by 2035?** A: The projected valuation for antibiotics in the treatment segment is $10.0 Million by 2035. **Q: What was the market valuation for hospitals & diagnostic centers in 2024?** A: The market valuation for hospitals & diagnostic centers was $4.92 Million in 2024. **Q: What is the projected valuation for the 'others' category in the diagnosis segment by 2035?** A: The projected valuation for the 'others' category in the diagnosis segment is $10.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/spain-brucellosis-market-53598*